Erlotinib
Links shared publicly online about this topic
FDA Alert: Tarceva (erlotinib)
drugs.com — “FDA Alert: Tarceva (erlotinib)” View full resource at drugs.com
Most Recently Shared on May 9, 2009 at 8:08 pm By:
FDA Alert - New Safety Information for Tarceva (erlotinib) - http://tinyurl.com/r355ox
Erlotinib Cancer Treatment Drug
disabled-world.com — “The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated” View full resource at disabled-world.com
Most Recently Shared on February 27, 2011 at 6:38 pm By:
Disabled World Health Advocate and Health News
Erlotinib Cancer Treatment Drug http://ff.im/-yZx2j
Erlotinib (Tarceva) - ONA
oncologynurseadvisor.com — “Erlotinib is a human epidermal growth factor receptor type 1/epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor approved for non-small cell lung cancer and pancreatic cancer.” View full resource at oncologynurseadvisor.com
Most Recently Shared on October 26, 2010 at 1:51 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Erlotinib (Tarceva) http://goo.gl/fb/TCSeW
Oncology Article | erlotinib
mdlinx.com — “Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children” View full resource at mdlinx.com
Most Recently Shared on June 10, 2011 at 12:32 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the... http://bit.ly/jVR0FI #oncology
Oncology Article | Erlotinib
mdlinx.com — “Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial” View full resource at mdlinx.com
Most Recently Shared on August 26, 2011 at 2:19 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carci... http://t.co/heI4T2e #oncology
Otolaryngology Article | Erlotinib
mdlinx.com — “Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial” View full resource at mdlinx.com
Most Recently Shared on August 25, 2011 at 4:58 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma ... http://t.co/3GUjT3L #ENT
TARCEVA (Erlotinib) drug information from MPR
empr.com — “TARCEVA (Erlotinib) drug information for Cancer, pancreatic, Neoplasms, Non-small cell lung cancer from MPR including side effects, drug interactions, dosing, contraindications and precautions.” View full resource at empr.com
Most Recently Shared on June 8, 2010 at 4:22 am By:
MPR News: TARCEVA: Indications: approved as maintenance therapy for advanced non-small cell lung cancer. http://bit.ly/A3cw6
Erlotinib Dosing In Lung Cancer Depends On Smoking Status
medicalnewstoday.com — “Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases. increased doses may lead to bet” View full resource at medicalnewstoday.com
Most Recently Shared on January 14, 2010 at 1:06 am By:
Erlotinib Dosing In Lung Cancer Depends On Smoking Status http://mnt.to/3wfm
Erlotinib dosing in lung cancer depends on smoking status
physorg.com — “Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.” View full resource at physorg.com
Most Recently Shared on January 13, 2010 at 4:59 am By:
Erlotinib dosing in lung cancer depends on smoking status http://bit.ly/8jiNJP
Erlotinib or Gefitinib for Lung Cancer | Now@NEJM
blogs.nejm.org — “The latest article in our Clinical Therapeutics series, Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib, comes from Dr. Vince Cataldo at the” View full resource at blogs.nejm.org
Most Recently Shared on March 11, 2011 at 6:01 pm By:
NEJM: Erlotinib or Gefitinib for Lung Cancer http://bit.ly/ek58rA
Erlotinib or Gefitinib for Lung Cancer | Now@NEJM
blogs.nejm.org — “The latest article in our Clinical Therapeutics series, Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib, comes from Dr. Vince Cataldo at the” View full resource at blogs.nejm.org
Most Recently Shared on March 13, 2011 at 3:05 pm By:
Robert S. Miller, MD Oncologist, Physician, Doctor, and Internist
NEJM: Erlotinib or Gefitinib for Lung Cancer http://t.co/OT3Jwuj-->clinical pearls
Quality of Life Significantly Improved with Erlotinib for NSCLC - MPR
empr.com — “Erlotinib improved progression-free survival when compared with gemcitabine + carboplatin as first-line treatment for EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer, according to the results of the OPTIMAL study presented at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at empr.com
Most Recently Shared on June 6, 2011 at 8:43 pm By:
#asco2011 Quality of Life Significantly Improved with Erlotinib for NSCLC http://goo.gl/fb/t31b1
Economic analysis: Erlotinib marginally cost-effective
physorg.com — “Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective. The results of their economic analysis using clinical trial ...” View full resource at physorg.com
Most Recently Shared on February 16, 2010 at 11:44 pm By:
Economic analysis: Erlotinib marginally cost-effective http://bit.ly/d66TBP
Erlotinib Found To Be Marginally Cost-Effective In Economic Analysis
medicalnewstoday.com — “Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell” View full resource at medicalnewstoday.com
Most Recently Shared on February 17, 2010 at 10:09 pm By:
MNT Clinical Trials Health News
Erlotinib Found To Be Marginally Cost-Effective In Economic Analysis http://mnt.to/3xKp #clinicaltrials
Early Results Show Erlotinib Extends Life For Women With Advanced Lung Cancer
medicalnewstoday.com — “Three times as many women with advanced lung cancer were alive and had no progressio” View full resource at medicalnewstoday.com
Most Recently Shared on June 8, 2010 at 2:05 pm By:
Early Results Show Erlotinib Extends Life For Women With Advanced Lung Cancer http://mnt.to/3DCW #healthnews
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Disabled World
Disabled World is managed by Lynn and Ian Langtree, a couple dedicated to assisting seniors and people with disabilities.
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
Advertisement
